{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":2,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"4e13faf04e63","filters":{"venue":"Tumors of female reproductive system"}},"results":[{"id":"W3136098766","doi":"10.17650/1994-4098-2020-16-3-72-80","title":"Lenvatinib and pembrolizumab in patients with advanced uterine cancer","year":2020,"lang":"en","type":"article","venue":"Tumors of female reproductive system","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Lenvatinib; Medicine; Endometrial cancer; Internal medicine; Adverse effect; Oncology; Population; Cancer; Gynecology; Immunotherapy; Thyroid cancer","authors":[{"name":"А. Г. Кедрова","is_ca":false},{"name":"А. И. Беришвили","is_ca":false},{"name":"Т. А. Greyan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01931137102402981,"gpt":0.2754692590850422,"spread":0.2561578880610124,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002162942,0.0001051701,0.0002813715,0.0002043777,0.0002397472,0.0001729292,0.00008349851,0.0003043349,0.0006074454],"category_scores_gemma":[0.0004825056,0.00005549644,0.0001774992,0.0002743696,0.0001200945,0.0001594729,0.0001380998,0.0003747671,0.0001050545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000202653,"about_ca_system_score_gemma":0.0002707168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006268307,"about_ca_topic_score_gemma":0.001707594,"domain_scores_codex":[0.9998889,0.00004103504,0.00001359546,0.0000136989,0.00002352389,0.00001933458],"domain_scores_gemma":[0.9999264,0.00002177234,0.0000184752,0.000003152665,0.000005841449,0.00002429274],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008713612,0.0009731353,0.4952128,0.0007009307,0.000345239,0.03220633,0.0008920994,0.000983907,0.03004326,0.0008359745,0.007843795,0.4212489],"study_design_scores_gemma":[0.001627687,0.01313215,0.7695572,0.0003583508,0.0005852592,0.1042526,0.0006946646,0.002138353,0.009500062,0.0009434482,0.09717321,0.00003700716],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9487142,0.03833171,0.0003735588,0.00221909,0.00008658635,0.00008987281,0.0001026411,0.00001917889,0.01006307],"genre_scores_gemma":[0.9906576,0.007129329,0.0003729023,0.0007897576,0.0001151273,0.00002564021,0.0001037635,0.000001959415,0.0008040285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0006268307,"threshold_uncertainty_score":0.002032042,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4410308781","doi":"10.17650/1994-4098-2025-21-1-123-131","title":"Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab","year":2025,"lang":"en","type":"article","venue":"Tumors of female reproductive system","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Oncology; Endometrial cancer; Internal medicine; Cancer; Immunotherapy","authors":[{"name":"Alexander Pawsey","is_ca":false},{"name":"Preethika Mahalingam","is_ca":false},{"name":"Nishanthi Senthivel","is_ca":false},{"name":"Anisha Ramessur","is_ca":true},{"name":"Elizabeth Turnbull","is_ca":false},{"name":"Shumaila Usman","is_ca":false},{"name":"Rodrigo Alberto Vieira Browne","is_ca":false},{"name":"Aisha S Patel","is_ca":false},{"name":"Alexandra Stewart","is_ca":false},{"name":"Laura A. Tookman","is_ca":false},{"name":"Nicholas Counsell","is_ca":false},{"name":"Robert F. Miller","is_ca":false},{"name":"Shibani Nicum","is_ca":false},{"name":"Gemma Eminowicz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02899208550226592,"gpt":0.3205094944435443,"spread":0.2915174089412784,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005250013,0.0001515191,0.0003675267,0.0002969251,0.0002392361,0.0007603872,0.0002276844,0.0003688786,0.001811312],"category_scores_gemma":[0.003182025,0.00009149696,0.0007222546,0.0005734761,0.0001863092,0.0005891549,0.0004504223,0.0007411141,0.0002193636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007546868,"about_ca_system_score_gemma":0.0004045093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003873183,"about_ca_topic_score_gemma":0.005972611,"domain_scores_codex":[0.9995752,0.0001647084,0.00004994975,0.00006541408,0.00005475965,0.00008996025],"domain_scores_gemma":[0.9988335,0.0002205313,0.0006057684,0.0000426014,0.00008483214,0.0002128848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008782216,0.0003406303,0.9460688,0.0003592997,0.001736968,0.0004490574,0.0001932529,0.001617371,0.0003464415,0.0003108193,0.005382243,0.03441304],"study_design_scores_gemma":[0.0004678043,0.002101179,0.9864559,0.000162154,0.0009080683,0.0009921093,0.000557068,0.001890992,0.000192346,0.000471253,0.005759048,0.00004198494],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985696,0.004816821,0.0001761501,0.000868947,0.00007944367,0.0000375704,0.00505778,0.00001023088,0.003257009],"genre_scores_gemma":[0.9954422,0.0007718074,0.0000782982,0.0001557832,0.00004882187,0.00002543607,0.003263634,0.000002643205,0.000211435],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003873183,"threshold_uncertainty_score":0.007701278,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}